Patent intelligence · US
US 9066883
Administration of cells and cellular extracts for rejuvenation
Administration of cells and cellular extracts for rejuvenation
Patent details — US 9066883
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 30, 2015
- Expiration
- Jun 25, 2035
- Applicant
- REGENICS AS
- Claims
- 8
- CPC classes
- A61K, A61K31/7088, A61K35/36, A61K35/60
Quick answer
US 9066883 (Administration of cells and cellular extracts for rejuvenation) is held by REGENICS AS. Status: granted. Granted Jun 30, 2015. Expires Jun 25, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENICS AS
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/7088, A61K35/36, A61K35/60, A61K38/02, A61K45/06
More from REGENICS AS
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 9066883?
US 9066883 (Administration of cells and cellular extracts for rejuvenation) is held by REGENICS AS. Status: granted. Granted Jun 30, 2015. Expires Jun 25, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9066883?
REGENICS AS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 9066883 expire?
Our index shows an expiration date of Jun 25, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.